PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti, Giorgio V.
Park, Keunchil
Patil, Shekar
Rolski, Janusz
Goksel, Tuncay
Martins, Renato
Gans, Steven J. M.
Visseren-Grul, Carla
Peterson, Patrick

January 2009

WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Gridelli, Cesare
de Marinis, Filippo
Pujol, Jean-Louis
Reck, Martin
Ramlau, Rodryg
Parente, Barbara
Pieters, Thierry
Middleton, Gary
Corral, Jesus
Winfree, Katherine
Melemed, Symantha
Zimmermann, Anna
John, William
Beyrer, Julie
Chouaki, Nadia
Visseren-Grul, Carla
Paz-Ares, Luis G.

November 2012

IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...

Real-World Maintenance Therapy and Survival Outcomes for Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA

Aggarwal, Himani
Bayo, KayOnda
Han, Yimei
Muehlenbein, Catherine Elizabeth
Zhu, Yajun Emily
Kim, Jong Seok

February 2023

Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Paz-Ares, Luis G.
Altug, Sedat.
Vaury, Alexandra T.
Jaime, Jesús C.
Russo, Francesca.
Visseren-Grul, Carla.

March 2010

TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Paz-Ares, Luis G.
Altug, Sedat.
Vaury, Alexandra T.
Jaime, Jesús C.
Russo, Francesca.
Visseren-Grul, Carla.

March 2010

TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Paz-Ares, Luis G.
Altug, Sedat.
Vaury, Alexandra T.
Jaime, Jesús C.
Russo, Francesca.
Visseren-Grul, Carla.

March 2010

TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer

Senan, Suresh
Brade, Anthony
Wang, Lu-Hua
Vansteenkiste, Johan
Dakhil, Shaker
Biesma, Bonne
Martinez Aguillo, Maite
Aerts, Joachim
Govindan, Ramaswamy
Rubio-Viqueira, Belén
Lewanski, Conrad
Gandara, David
Choy, Hak
Mok, Tony
Hossain, Anwar
Iscoe, Neill
Treat, Joseph
Koustenis, Andrew
San Antonio, Bélen
Chouaki, Nadia
Vokes, Everett

March 2016

The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and ...

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer

Senan, Suresh
Brade, Anthony
Wang, Lu-Hua
Vansteenkiste, Johan
Dakhil, Shaker
Biesma, Bonne
Martinez Aguillo, Maite
Aerts, Joachim
Govindan, Ramaswamy
Rubio-Viqueira, Belén
Lewanski, Conrad
Gandara, David
Choy, Hak
Mok, Tony
Hossain, Anwar
Iscoe, Neill
Treat, Joseph
Koustenis, Andrew
San Antonio, Bélen
Chouaki, Nadia
Vokes, Everett

March 2016

The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and ...

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Pujol, Jean-Louis
Paz-Ares, Luis
de Marinis, Filippo
Dediu, Mircea
Thomas, Michael
Bidoli, Paolo
Corral, Jesus
San Antonio, Belen
Chouaki, Nadia
John, William
Zimmermann, Annamaria
Visseren-Grul, Carla
Gridelli, Cesare

November 2014

AbstractIntroductionIn the PARAMOUNT (“A Phase 3, Double-Blind, Placebo-Controlled Study of Maintena...

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Gridelli, Cesare
de Marinis, Filippo
Pujol, Jean-Louis
Reck, Martin
Ramlau, Rodryg
Parente, Barbara
Pieters, Thierry
Middleton, Gary
Corral, Jesus
Winfree, Katherine
Melemed, Symantha
Zimmermann, Anna
John, William
Beyrer, Julie
Chouaki, Nadia
Visseren-Grul, Carla
Paz-Ares, Luis G.

November 2012

IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti G.V.
Park K.
Patil S.
Rolski J.
Goksel T.
Martins R.
Gans S.J.M.
Visseren-Grul C.
Peterson P.

January 2009

PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetrexed had non-inferior...

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

김주항

January 2009

BACKGROUND: Several studies have shown the efficacy, tolerability, and ease of administration of pem...

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti, Giorgio V.
Park, Keunchil
Patil, Shekar
Rolski, Janusz
Goksel, Tuncay
Martins, Renato
Gans, Steven J. M.
Visseren-Grul, Carla
Peterson, Patrick

January 2009

WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti, Giorgio V.
Park, Keunchil
Patil, Shekar
Rolski, Janusz
Goksel, Tuncay
Martins, Renato
Gans, Steven J. M.
Visseren-Grul, Carla
Peterson, Patrick

January 2009

WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Gridelli, Cesare
de Marinis, Filippo
Pujol, Jean-Louis
Reck, Martin
Ramlau, Rodryg
Parente, Barbara
Pieters, Thierry
Middleton, Gary
Corral, Jesus
Winfree, Katherine
Melemed, Symantha
Zimmermann, Anna
John, William
Beyrer, Julie
Chouaki, Nadia
Visseren-Grul, Carla
Paz-Ares, Luis G.

November 2012

IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...

Real-World Maintenance Therapy and Survival Outcomes for Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA

Aggarwal, Himani
Bayo, KayOnda
Han, Yimei
Muehlenbein, Catherine Elizabeth
Zhu, Yajun Emily
Kim, Jong Seok

February 2023

Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Paz-Ares, Luis G.
Altug, Sedat.
Vaury, Alexandra T.
Jaime, Jesús C.
Russo, Francesca.
Visseren-Grul, Carla.

March 2010

TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Paz-Ares, Luis G.
Altug, Sedat.
Vaury, Alexandra T.
Jaime, Jesús C.
Russo, Francesca.
Visseren-Grul, Carla.

March 2010

TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Paz-Ares, Luis G.
Altug, Sedat.
Vaury, Alexandra T.
Jaime, Jesús C.
Russo, Francesca.
Visseren-Grul, Carla.

March 2010

TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer

Senan, Suresh
Brade, Anthony
Wang, Lu-Hua
Vansteenkiste, Johan
Dakhil, Shaker
Biesma, Bonne
Martinez Aguillo, Maite
Aerts, Joachim
Govindan, Ramaswamy
Rubio-Viqueira, Belén
Lewanski, Conrad
Gandara, David
Choy, Hak
Mok, Tony
Hossain, Anwar
Iscoe, Neill
Treat, Joseph
Koustenis, Andrew
San Antonio, Bélen
Chouaki, Nadia
Vokes, Everett

March 2016

The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and ...

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer

Senan, Suresh
Brade, Anthony
Wang, Lu-Hua
Vansteenkiste, Johan
Dakhil, Shaker
Biesma, Bonne
Martinez Aguillo, Maite
Aerts, Joachim
Govindan, Ramaswamy
Rubio-Viqueira, Belén
Lewanski, Conrad
Gandara, David
Choy, Hak
Mok, Tony
Hossain, Anwar
Iscoe, Neill
Treat, Joseph
Koustenis, Andrew
San Antonio, Bélen
Chouaki, Nadia
Vokes, Everett

March 2016

The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and ...

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Pujol, Jean-Louis
Paz-Ares, Luis
de Marinis, Filippo
Dediu, Mircea
Thomas, Michael
Bidoli, Paolo
Corral, Jesus
San Antonio, Belen
Chouaki, Nadia
John, William
Zimmermann, Annamaria
Visseren-Grul, Carla
Gridelli, Cesare

November 2014

AbstractIntroductionIn the PARAMOUNT (“A Phase 3, Double-Blind, Placebo-Controlled Study of Maintena...

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Gridelli, Cesare
de Marinis, Filippo
Pujol, Jean-Louis
Reck, Martin
Ramlau, Rodryg
Parente, Barbara
Pieters, Thierry
Middleton, Gary
Corral, Jesus
Winfree, Katherine
Melemed, Symantha
Zimmermann, Anna
John, William
Beyrer, Julie
Chouaki, Nadia
Visseren-Grul, Carla
Paz-Ares, Luis G.

November 2012

IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti G.V.
Park K.
Patil S.
Rolski J.
Goksel T.
Martins R.
Gans S.J.M.
Visseren-Grul C.
Peterson P.

January 2009

PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetrexed had non-inferior...

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

김주항

January 2009

BACKGROUND: Several studies have shown the efficacy, tolerability, and ease of administration of pem...

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti, Giorgio V.
Park, Keunchil
Patil, Shekar
Rolski, Janusz
Goksel, Tuncay
Martins, Renato
Gans, Steven J. M.
Visseren-Grul, Carla
Peterson, Patrick

January 2009

WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Scagliotti, Giorgio V.
Park, Keunchil
Patil, Shekar
Rolski, Janusz
Goksel, Tuncay
Martins, Renato
Gans, Steven J. M.
Visseren-Grul, Carla
Peterson, Patrick

January 2009

WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Gridelli, Cesare
de Marinis, Filippo
Pujol, Jean-Louis
Reck, Martin
Ramlau, Rodryg
Parente, Barbara
Pieters, Thierry
Middleton, Gary
Corral, Jesus
Winfree, Katherine
Melemed, Symantha
Zimmermann, Anna
John, William
Beyrer, Julie
Chouaki, Nadia
Visseren-Grul, Carla
Paz-Ares, Luis G.

November 2012

IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...

Real-World Maintenance Therapy and Survival Outcomes for Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA

Aggarwal, Himani
Bayo, KayOnda
Han, Yimei
Muehlenbein, Catherine Elizabeth
Zhu, Yajun Emily
Kim, Jong Seok

February 2023

Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung

Abstract

Extracted data

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung

Abstract

Extracted data

Related items

Related items